Claritev revenue and EBITDA grow as healthcare transparency demand increases

Claritev (NYSE:CTEV) reported modest top-line growth for the first quarter of 2026, as the company continues to scale its data and insights platform aimed at healthcare affordability.

The New York-based technology firm posted total revenue of $244.7 million for the quarter ended March 31, 2026, a 5.8% increase compared to the $231.3 million recorded in the first quarter of 2025.

Operational profitability showed steady improvement on an adjusted basis, with adjusted EBITDA rising 3.4% to $146.9 million.

However, the company’s bottom line remained under pressure.

Claritev reported a net loss of $73.6 million for the period, a slight widening from the $71.3 million loss reported in the prior-year quarter, reflecting ongoing investments in its technology stack and high interest expenses.

The company’s cash metrics highlighted the capital-intensive nature of its current growth phase.

Net cash used in operating activities reached $45.8 million, up from $30.1 million in the first quarter of 2025.

Free cash flow for the quarter was negative $92.5 million, compared to negative $68.9 million a year ago.

Claritev ended the first quarter with $21.3 million of unrestricted cash and cash equivalents on its balance sheet.